Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$19.95 - $31.0 $53,047 - $82,429
-2,659 Reduced 1.91%
136,465 $3.94 Million
Q3 2023

Nov 14, 2023

SELL
$21.33 - $59.42 $9.21 Million - $25.7 Million
-431,932 Reduced 75.64%
139,124 $3.19 Million
Q2 2023

Aug 14, 2023

BUY
$34.33 - $62.11 $9.13 Million - $16.5 Million
265,818 Added 87.09%
571,056 $32.7 Million
Q1 2023

May 15, 2023

BUY
$26.01 - $48.69 $4.81 Million - $9.01 Million
185,050 Added 153.97%
305,238 $11.5 Million
Q4 2022

Feb 14, 2023

SELL
$24.14 - $30.37 $38,744 - $48,743
-1,605 Reduced 1.32%
120,188 $3.22 Million
Q3 2022

Nov 14, 2022

SELL
$22.23 - $33.37 $69,246 - $103,947
-3,115 Reduced 2.49%
121,793 $3.45 Million
Q2 2022

Aug 15, 2022

SELL
$19.74 - $43.01 $5.1 Million - $11.1 Million
-258,609 Reduced 67.43%
124,908 $2.71 Million
Q1 2022

May 16, 2022

SELL
$36.25 - $52.02 $4.82 Million - $6.92 Million
-132,956 Reduced 25.74%
383,517 $15.4 Million
Q4 2021

Feb 14, 2022

BUY
$43.27 - $65.72 $2.33 Million - $3.54 Million
53,802 Added 11.63%
516,473 $24.5 Million
Q3 2021

Nov 15, 2021

BUY
$53.61 - $67.5 $2.63 Million - $3.31 Million
49,082 Added 11.87%
462,671 $26.2 Million
Q2 2021

Aug 16, 2021

BUY
$45.13 - $64.99 $9.4 Million - $13.5 Million
208,352 Added 101.52%
413,589 $23.7 Million
Q1 2021

May 17, 2021

BUY
$29.77 - $84.85 $4.99 Million - $14.2 Million
167,737 Added 447.3%
205,237 $13 Million
Q4 2020

Feb 16, 2021

BUY
$25.66 - $34.55 $962,250 - $1.3 Million
37,500 New
37,500 $1.26 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Driehaus Capital Management LLC Portfolio

Follow Driehaus Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.